The cost of Mounjaro (tirzepatide) in Ontario varies. It is not currently listed on the Ontario Drug Benefit (ODB) Formulary, meaning it is generally not covered by public drug plans [1]. Patients typically purchase Mounjaro through private insurance or pay out-of-pocket.
What is the typical cash price for Mounjaro?
Without public coverage, the out-of-pocket cost for a 4-week supply of Mounjaro can range from approximately $280 to $300 CAD [1]. This price can fluctuate based on the pharmacy and any available manufacturer discounts or patient assistance programs.
Does private insurance cover Mounjaro in Ontario?
Coverage for Mounjaro through private insurance plans in Ontario depends on the specific policy. Many plans may cover Mounjaro, but often require prior authorization from the insurance provider [1]. Patients should verify their coverage details with their insurance provider.
Are there programs to help with the cost of Mounjaro?
Eli Lilly, the manufacturer of Mounjaro, offers a savings card program that can reduce the out-of-pocket cost for eligible patients. This program may offer savings of up to $200 per month for those with commercial drug insurance [1]. Information on eligibility and how to apply for these savings programs is available from the manufacturer or at pharmacies.
What are the dosage strengths of Mounjaro and how does that affect cost?
Mounjaro is available in several dosage strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Each pen delivers a single dose. The cost is typically per pen or per pack of four pens, with higher dosages generally costing the same as lower dosages for the same supply duration [1].
When might Mounjaro be covered by Ontario's public drug plan?
Eligibility for the Ontario Drug Benefit (ODB) Formulary is subject to review and listing by the Ontario Ministry of Health. As of current information, Mounjaro is not on the ODB Formulary for general public coverage. Inclusion on the formulary typically follows extensive clinical trial data and health technology assessments [1].
How does Mounjaro work, and what is it prescribed for?
Mounjaro is a dual GIP and GLP-1 receptor agonist. It is prescribed for adults with type 2 diabetes mellitus to improve glycemic control [2]. It works by stimulating insulin secretion, reducing glucagon secretion, slowing gastric emptying, and increasing satiety, thereby lowering blood glucose levels.
What are the common side effects of Mounjaro?
Common side effects of Mounjaro can include nausea, vomiting, diarrhea, abdominal pain, and constipation. These are often mild to moderate and tend to decrease over time [2].
What is the patent status of Mounjaro?
Information regarding the patent status and expiry dates for Mounjaro can be found on specialized databases like DrugPatentWatch.com [3]. Patents protect the drug from generic competition, influencing when lower-cost biosimilar versions might become available.
Who manufactures Mounjaro?
Mounjaro is manufactured by Eli Lilly and Company [1, 2].
Sources:
1. DrugPatentWatch.com
2. Eli Lilly and Company. Mounjaro prescribing information.
3. DrugPatentWatch.com